Sobi/Biogen and CSL Behring poised for battle in European hemophilia B

24 March 2016

Two new products for the treatment of hemophilia B, CSL Ltd (ASX: CSL) subsidiary CSL Behring’s Idelvion (coagulation Factor IX [recombinant] and Alprolix (eftrenonacog alfa), from Swedish Orphan Biovitrum (STO: SOBI) and Biogen (Nasdaq: BIIB), will compete intensely for market share following their expected European Union approvals in April 2016.

According to an analyst with research and consulting firm GlobalData, while Idelvion had a three-month head-start over Alprolix in the European Medicines Agency’s review process, Alprolix managed to catch up and obtained a recommendation from the Committee for Medicinal Products for Human Use at the same time as Idelvion.

Fenix Leung, GlobalData’s senior analyst covering oncology and hematology, states that as the efficacy and safety of both Idelvion and Alprolix are considered to be very similar according to key opinion leaders interviewed by GlobalData, the time to market will be a key differentiator in determining the success of a drug in the hemophilia B market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK